Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer

Journals Menu

Follow SCIRP

ISSN Print: 2160-5815
ISSN Online: 2160-5823
www.scirp.org/journal/wjv
E-mail: wjv@scirp.org

"Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer"
written by Nathalie Machluf, Ruth Arnon,
published by World Journal of Vaccines, Vol.2 No.3, 2012

has been cited by the following article(s):

[1]	MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
	Cancer Cell …, 2022

[2]	Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model
	2020

[3]	Fusion of bacterial flagellin to a dendritic cell-targeting αCD40 antibody construct coupled with viral or leukemia-specific antigens enhances dendritic cell …
	2020

[4]	Novel multifunctional antibody constructs combining antigen and adjuvant delivery to dendritic cells as a therapeutic vaccine
	2020

[5]	Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
	Molecular Therapy, 2018

[6]	Bacterial flagellin-a potent immunomodulatory agent.
	Experimental & molecular medicine, 2017

[7]	Bacterial flagellin—a potent immunomodulatory agent
	Experimental & Molecular Medicine, 2017

[8]	Enhancement of anti-tumor effect of particulate vaccine delivery system by'bacteriomimetic'CpG functionalization of poly-lactic-co-glycolic acid nanoparticles
	Nanomedicine, 2015

[9]	Formulation, characterization and validation of CpG functionalized PLGA bacteriomimetic nanoparticles for breast cancer immunotherapy
	2015

[10]	Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic'CpG functionalization of poly-lactic-co-glycolic acid nanoparticles
	2015

[11]	Dendritic Cells Primed with Protein–Protein Fusion Adjuvant
	Cancer Vaccines. Springer, 2014

[1]	Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model Human Vaccines & Immunotherapeutics, 2021 DOI:10.1080/21645515.2020.1763693

[2]	Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells Frontiers in Immunology, 2020 DOI:10.3389/fimmu.2020.602802

[3]	Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer Molecular Therapy, 2018 DOI:10.1016/j.ymthe.2017.10.020

[4]	Bacterial flagellin—a potent immunomodulatory agent Experimental & Molecular Medicine, 2017 DOI:10.1038/emm.2017.172

[5]	Enhancement of anti-tumor effect of particulate vaccine delivery system by ‘bacteriomimetic’ CpG functionalization of poly-lactic-co-glycolic acid nanoparticles Nanomedicine, 2015 DOI:10.2217/nnm.14.144

[6]	Cancer Vaccines Methods in Molecular Biology, 2014 DOI:10.1007/978-1-4939-0345-0_7

Follow SCIRP